Zobrazeno 1 - 10
of 63
pro vyhledávání: '"George E. Duran"'
Autor:
Tianying Su, George E. Duran, Alexa C. Kwang, Nirasha Ramchurren, Steven P. Fling, Youn H. Kim, Michael S. Khodadoust
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to disco
Externí odkaz:
https://doaj.org/article/0320d623a02c4a77b456894a308c9fc9
Autor:
Hitomi Hosoya, Mia Carleton, Kailee L Tanaka, Brian Sworder, Vanna Hovanky, George E Duran, Tian Y. Zhang, Michael S. Khodadoust, David B. Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David M. Kurtz
Publikováno v:
Blood. 140:1546-1548
Autor:
George E Duran, Branimir I Sikic
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210879 (2019)
In a previously published study, higher levels of spleen tyrosine kinase (Syk) were observed in recurrent post-chemotherapy ovarian cancers compared to primary tumors. Syk inhibition was found to stabilize microtubules and potentiate paclitaxel activ
Externí odkaz:
https://doaj.org/article/870fe4763b2542db8e11e7d83f9d5486
Autor:
Branimir I. Sikic, Patricia Vrignaud, Diana Brassard, John Coller, Francisco J. Martinez, John C. Rose, E. Brian Francisco, Yan C. Wang, George E. Duran
The supplementary data include one table and 5 figures. Table S1 presents cabazitaxel cytotoxic activity in the human breast cancer cell line MCF-7, uterine sarcoma cell line MES-SA, and ovarian cancer cell lines ES-2, MES-OV, and OVCAR-3. Figure S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2b0d1bf1df6cb80f1b6337b788ba3c5
https://doi.org/10.1158/1535-7163.22502196
https://doi.org/10.1158/1535-7163.22502196
Autor:
Mia Carleton, Hitomi Hosoya, Kailee L. Tanaka, Brian Sworder, Vanna Hovanky, Bita Sahaf, Matthew J. Frank, George E. Duran, Tian Y. Zhang, Sally Arai, David Iberri, Michaela Liedtke, David B. Miklos, Michael S. Khodadoust, Surbhi Sidana, David M. Kurtz
Publikováno v:
Cancer Research. 83:5707-5707
Background: Multiple myeloma (MM) is an incurable disease with a heterogenous clinical course and genomic landscape. Autologous anti-BCMA chimeric antigen receptor (CAR) T-cells are a promising new therapy, but determinants of response and resistance
Autor:
Hitomi Hosoya, Mia Carleton, Kailee Tanaka, Brian Sworder, Vanna Hovanky, George E Duran, Tian Y Zhang, Michael Khodadoust, David B. Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David Kurtz
Publikováno v:
Transplantation and Cellular Therapy. 29:S1
Autor:
Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust
Publikováno v:
Blood. 139(26)
Mogamulizumab is a humanized anti–CC chemokine receptor 4 (CCR4) antibody approved for the treatment of mycosis fungoides and Sézary syndrome. Despite almost universal expression of CCR4 in these diseases, most patients eventually develop resistan
Autor:
Sebastian Fernandez-Pol, Henning Stehr, Martin A. Cheever, Steven P. Fling, James L. Zehnder, Nirasha Ramchurren, Michael S. Khodadoust, Sara Beygi, Wen-Kai Weng, Youn H. Kim, George E. Duran, Erica B Wang
Publikováno v:
Blood Adv
Key Points PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation. PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.
Autor:
Kevin G. Chen, Mark J. Mogul, Yan C. Wang, Jean-Pierre Jaffrézou, Kory R. Johnson, Tito Fojo, Lyn M. Huff, George E. Duran, Kevin L. Ross, Norman J. Lacayo, Branimir I. Sikic
Publikováno v:
Cancer Drug Resistance
Cancer Drug Resistance, OAE Publishing Inc., 2020, ⟨10.20517/cdr.2020.51⟩
Cancer Drug Resist
Cancer Drug Resistance, OAE Publishing Inc., 2020, ⟨10.20517/cdr.2020.51⟩
Cancer Drug Resist
AIM: Despite considerable efforts to reverse clinical multidrug resistance (MDR), targeting the predominant multidrug transporter ABCB1/P-glycoprotein (P-gp) using small molecule inhibitors has been unsuccessful, possibly due to the emergence of alte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96928db9bde4e11a5fb04d0898cdc77d
https://hal.archives-ouvertes.fr/hal-03065007
https://hal.archives-ouvertes.fr/hal-03065007
Autor:
Diego A. Gianolio, Volker Derdau, Nicolas Philippe, George E. Duran, Jens Atzrodt, Dietmar Weitz, Jörg Blankenstein, Dorothée Semiond, Sandrine Mace, Branimir I. Sikic
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:1095-1103
The primary aim of this study was to determine cabazitaxel’s affinity for the ABCB1/P-glycoprotein (P-gp) transporter compared to first-generation taxanes. We determined the kinetics of drug accumulation and retention using [14C]-labeled taxanes in